文献速递神经肌肉病

遗传性周围神经病中的血浆神经丝轻链蛋白浓度

Plasma neurofilament light chain concentration in the inherited peripheral neuropathies.
PubMed 文献 · Neurology · 2018-01-10

该横断面研究纳入75例腓骨肌萎缩症(CMT)患者和67名年龄匹配健康对照,检测血浆神经丝轻链蛋白(NfL)浓度。患者中位浓度26.0 pg/mL,显著高于对照的14.6 pg/mL(p < 0.0001),并与Rasch改良CMT检查评分(r = 0.43,p < 0.0001)和神经病评分(r = 0.37,p = 0.044)相关。作者认为血浆NfL有望作为遗传性周围神经病及一般周围神经病的疾病活动性生物标志物。

要点

  • CMT患者血浆NfL中位26.0 pg/mL,显著高于健康对照的14.6 pg/mL(p < 0.0001)。
  • 血浆NfL与Rasch改良CMT检查评分(r = 0.43,p < 0.0001)和神经病评分(r = 0.37,p = 0.044)相关。
  • 按遗传亚型(CMT1A、SPTLC1、GJB1)或脱髓鞘/轴索型分组,NfL均显著高于健康对照。

核心结论

  • CMT患者血浆NfL浓度显著升高,且与疾病严重程度相关,提示其有望作为遗传性周围神经病及一般周围神经病的疾病活动性生物标志物。

研究设计与样本

  • 横断面研究,在1年期间收集75例CMT患者和67名年龄匹配健康对照的血样,用内部开发的Simoa法检测血浆NfL浓度,用Rasch改良CMT检查和神经病评分评估疾病严重程度。

主要发现

  • CMT患者血浆NfL中位浓度为26.0 pg/mL,健康对照为14.6 pg/mL,患者显著高于对照(p < 0.0001)。
  • 血浆NfL与Rasch改良CMT检查评分相关(r = 0.43,p < 0.0001),与神经病评分相关(r = 0.37,p = 0.044)。
  • 按遗传亚型(CMT1A、SPTLC1、GJB1)或分为脱髓鞘型与轴索型后,各亚组患者NfL浓度均显著高于健康对照。

临床怎么用

  • 目前尚无经过验证的周围神经病血液生物标志物;作者认为血浆NfL有望作为遗传性周围神经病及一般周围神经病的疾病活动性生物标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To perform a cross-sectional study to determine whether plasma neurofilament light chain (NfL) concentration is elevated in patients with Charcot-Marie-Tooth disease (CMT) and if it correlates with disease severity. METHODS: Blood samples were collected from 75 patients with CMT and 67 age-matched healthy controls over a 1-year period. Disease severity was measured using the Rasch modified CMT Examination and neuropathy scores. Plasma NfL concentration was measured using an in-house-developed Simoa assay. RESULTS: Plasma NfL concentration was significantly higher in patients with CMT (median 26.0 pg/mL) compared to healthy controls (median 14.6 pg/mL, p < 0.0001) and correlated with disease severity as measured using the Rasch modified CMT examination (r = 0.43, p < 0.0001) and neuropathy (r = 0.37, p = 0.044) scores. Concentrations were also significantly higher when subdividing patients by genetic subtype (CMT1A, SPTLC1, and GJB1) or into demyelinating or axonal forms compared to healthy controls. CONCLUSION: There are currently no validated blood biomarkers for peripheral neuropathy. The significantly raised plasma NfL concentration in patients with CMT and its correlation with disease severity suggest that plasma NfL holds promise as a biomarker of disease activity, not only for inherited neuropathies but for peripheral neuropathy in general.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Sandelius Å, Zetterberg H, Blennow K, et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. 2018. PMID: 29321234. doi:10.1212/WNL.0000000000004932

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。